Bellicum Pharmaceuticals, Inc. (BLCM) financial statements (2022 and earlier)

Company profile

Business Address 3730 KIRBY DRIVE
HOUSTON, TX 77098
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments46,15635,49591,02892,99938,83933,14070,241
Cash and cash equivalents46,15635,49591,02843,69538,83933,14070,241
Short-term investments   49,304   
Restricted cash and investments1,5011,5012,788    
Assets held-for-sale, not part of disposal group 1,64316,851    
Other undisclosed current assets1,4748041,1872,29662,81172,47026,649
Total current assets:49,13139,443111,85495,295101,650105,61096,890
Noncurrent Assets
Operating lease, right-of-use asset 6451,042
Property, plant and equipment121892,52920,87825,94216,5046,882
Long-term investments and receivables    1,368 56,304
Long-term investments    1,368 56,304
Restricted cash and investments   4,9736,1909,640 
Other noncurrent assets 307825355378283330
Total noncurrent assets:121,1414,39626,20633,87826,42763,516
TOTAL ASSETS:49,14340,584116,250121,501135,528132,037160,406
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3,8494,1659,77012,3639,67912,9867,186
Accounts payable   3,7743,2873,6232,106
Accrued liabilities   8,5896,3929,3635,080
Employee-related liabilities3201,0292,032    
Other undisclosed accounts payable and accrued liabilities3,5293,1367,738    
Debt  11,00040311,80813
Deferred rent credit   418
Derivative instruments and hedges, liabilities2,77310,34552,184    
Deferred revenue and credits2,446319246
Contract with customer, liability2,983
Other undisclosed current liabilities9010,19121,464    
Total current liabilities:6,71224,70194,41815,80412,15615,1137,445
Noncurrent Liabilities
Long-term debt and lease obligation  25,71735,92335,077141118
Long-term debt, excluding current maturities  25,71735,83234,946  
Capital lease obligations91131141118
Liabilities, other than long-term debt   1,2963,6471,773826
Deferred revenue and credits3,6471,773826
Deferred rent credit   1,296
Other undisclosed noncurrent liabilities 344864  18,436 
Total noncurrent liabilities: 34426,58137,21938,72420,350944
Total liabilities:6,71225,045120,99953,02350,88035,4638,389
Temporary equity, carrying amount18,03618,03621,468    
Stockholders' equity
Stockholders' equity attributable to parent24,395(2,497)(26,217)68,47884,64896,574152,017
Common stock8584507442340278276
Treasury stock, value(5,056)(5,056)(5,056)(5,056)(5,056)(5,056)(5,056)
Additional paid in capital580,156543,561511,684493,784411,922332,068318,591
Accumulated other comprehensive income (loss)(338)(339)(327)(144)(46)17(302)
Accumulated deficit(550,452)(540,747)(533,025)(420,548)(322,512)(230,733)(161,492)
Total stockholders' equity:24,395(2,497)(26,217)68,47884,64896,574152,017
TOTAL LIABILITIES AND EQUITY:49,14340,584116,250121,501135,528132,037160,406

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues322,3917,1431,639185388282
Revenue, net185388282
Net investment income32 1,3511,639   
Other operating income 2,391     
Cost of revenue
(Cost of Goods and Services Sold)
   (436) (580)(3,184)
Gross profit:322,3917,1431,203185(192)(2,902)
Operating expenses(30,588)(54,583)(94,507)(96,586)(87,572)(68,768)(49,417)
Other operating expense, net(478)      
Other undisclosed operating income (loss)6,168500 (83) 5803,184
Operating loss:(24,866)(51,692)(87,364)(95,466)(87,387)(68,380)(49,135)
Nonoperating income (expense)15,16143,970(25,113)(2,570)(4,392)(861)587
Interest and debt expense(4)112(4,280)(4,199)(1,786)(1,760)(12)
Net loss:(9,709)(7,610)(116,757)(102,235)(93,565)(71,001)(48,560)
Other undisclosed net income (loss) attributable to parent4(112)4,2804,1991,7861,76012
Net loss available to common stockholders, diluted:(9,705)(7,722)(112,477)(98,036)(91,779)(69,241)(48,548)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(9,709)(7,610)(116,757)(102,235)(93,565)(71,001)(48,560)
Other comprehensive loss  (112,660)(98,134)(91,842)(68,922)(48,850)
Comprehensive loss:(9,709)(7,610)(229,417)(200,369)(185,407)(139,923)(97,410)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent5(124)116,757102,23593,56571,00148,560
Comprehensive loss, net of tax, attributable to parent:(9,704)(7,734)(112,660)(98,134)(91,842)(68,922)(48,850)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: